Novavax Inc. closed 69.57% short of its 52-week high of $23.86, which the company achieved on June 6th.

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

User Agreement; Privacy Policy; Ad Choices; Site Map © 2025 American City Business Journals. All rights reserved. Use of ...

Shares of Novavax Inc. NVAX slid 6.23% to $6.92 Wednesday, on what proved to be an all-around grim trading session for the ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who ...

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX is a Buy.

FDA Gives Full OK to Novavax COVID Shot for High-Risk Groups MONDAY, May 19, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax’s COVID-19 vaccine ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

The restrictions on Novavax's vaccine could portend changes at the FDA. Commissioner Marty Makary suggested last week that the agency could update its vaccine approval guidelines “in the coming days.” ...

Novavax's shot is now fully approved in the U.S. Since 2022, the vaccine has been used under an emergency use authorization.

Novavax shares jumped 16.6% to $7.84 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Markets expect rate cuts — but your earnings don’t have to suffer. Lock ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad population the company had originally sought. | The FDA has approved Novavax’s ...